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be comparable with published costings for the use of st-
atins to treat hypercholestolemia.
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COST-EFFECTIVENESS OF DOXAZOSIN IN 
COMBINATION THERAPY FOR HYPERTENSION 
TREATMENT IN DIABETIC PATIENTS IN THE UK
Casciano J1, Doyle J1, Casciano R1, Kopp S2, Arikian S1, 
Marchant N3, Kim R1
1Analytica Group, New York, NY, USA; 2Pfizer, New York, NY, 
USA; 3Pfizer, Sandwich, UK
OBJECTIVE: It is hypothesized that doxazosin’s positive
impact on lipid metabolism, in addition to its antihyper-
tensive effect, will result in a reduced risk of macrovascular
complications in type 2 diabetics, and an improved cost-
effectiveness profile from the NHS perspective when in-
cluded as a part of a combination drug therapy. METH-
ODS: A Markov model was constructed to simulate the
outcomes of patients on drug combinations over the
course of 10 years. Combination therapies examined in
this analysis were: (1) captopril, frusemide, nifedipine;
(2) atenolol, frusemide, nifedipine; and (3) minimal drug
therapy. The effect of substituting doxazosin in place of
any of these drugs was analyzed. Clinical outcomes con-
sidered included stroke, MI, heart failure, angina, PVD,
and death. Transitional probabilities were based on risk
rates presented in UKPDS 38. Risk rates were adjusted
for age and lipid lowering properties of doxazosin using
Framingham risk equations. The Treatment of Mild Hy-
pertension Study was used to quantify the effect of dox-
azosin on lipid levels. Costs of outcomes were calculated
using a Delphi panel to quantify resource consumption
and economic publications to estimate resource values
from the perspective of the NHS. RESULTS: Patients
who incorporated doxazosin into their combination ther-
apy saved 0.36 additional life-years compared to patients
on other combination regimens. This was achieved at in-
cremental costs ranging from £796–£1,741, which re-
sulted in incremental cost-effectiveness ratios of £2,224–
£4,867. When compared to patients on minimal drug
therapy, patients treated with doxazosin saved 0.71 addi-
tional life-years. This was achieved at incremental costs
ranging from £1,124–£2,089, which led to incremental
cost-effectiveness ratios of £1,574–£2,925. CONCLU-
SIONS: In the UK, the inclusion of doxazosin into an an-
tihypertensive combination drug therapy is predicted to
reduce morbidity and mortality due to diabetic mac-
rovascular complications through a marginal investment
in cost.
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ECONOMIC EVALUATION OF RAMIPRIL IN THE 
TREATMENT OF PATIENTS AT HIGH RISK OF 
CARDIOVASCULAR EVENTS
Backhouse ME, Richter A, Gaffney L
Research Triangle Institute, Manchester, UK
Recently, the Heart Outcomes Prevention Evaluation
(HOPE) trial, a randomized double-blind placebo con-
trolled trial in patients at high risk for cardiovascular
events but who did not have left ventricular dysfunction
or heart failure, demonstrated significant survival and
morbidity benefits associated with ramipril use in the
treatment of these patients. OBJECTIVE: To perform an
economic evaluation of ramipril in the treatment of pa-
tients at high risk of cardiovascular events. METHODS:
A decision analytic model was developed based on the re-
sults reported from the HOPE trial. Data from the trial
were combined with NHS cost data to produce estimates
of the potential incremental cost per life-year saved (IC-
PLYS). Both costs and benefits were discounted at 6%
and both discounted and undiscounted results are pre-
sented. Sensitivity analyses were performed to assess the
robustness of the results to key parameter values. RE-
SULTS: Based on a life—expectancy of 5.89 years esti-
mated for those surviving the trial at 5 years, our base
case estimate of cost-effectiveness is £4,406 per life-year
saved (undiscounted) and £5,544 per life-year saved (dis-
counted). The results were most sensitive to assumptions
around life expectancy of those patients who avoided
death through taking ramipril, and insensitive to the up-
per and lower bounds of costs and clinical events.
CONCLUSIONS: The economic analysis reported here
used clinical outcomes from an RCT together with eco-
nomic data from secondary sources in order to compare
the potential costs and effectiveness of using ramipril or
conventional treatment to treat CVD in high-risk pa-
tients. Based on our base case estimate of £6,327 per life-
year saved (discounted), the findings suggest that treating
patients at high risk of CVD events with ramipril is likely
to be a good investment of NHS resources.
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OBJECTIVES: To evaluate the gender-based differences
in the quality of life (QL) and compliance (C) with rou-
tine ambulatory management of essential hypertensives
(EH) living in Belarus, a European country with unique
combination of the important rise in cardiovascular mor-
bidity and mortality, highly restricted financing the state
health care system, and the society experiencing socio-
economic hardships. METHODS: In 234 verified mild to
moderate EH (mean age 47.8  12.2 years, 117 males,
117 females) the QL assessment was performed using the
well-validated, self-administered questionnaires: The Giessen
Somatic Complaints Questionnaire (GSC) and The Gen-
eral Well-Being Adjustment Scale (GWB). At the same
time, C with previously recommended antihypertensive
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treatment regimens was evaluated by the standardized in-
terview. RESULTS: The QL tests revealed significantly
(Mann-Whitney) worse QL scores on all GSC and GWB
subscales in the investigated Belarusian female EH compared
with male ones (Gastral Complaints, Pains, Cardiac Com-
plaints, Exhaustion, Anxiety, Depression, Well-Being, Self-
Control, General Health, Vitality) with the total GSC In-
dex (mean  SD) 35.9  17.2 vs. 21.1  13.5 points (P 
0.001), and the total GWB index 76.2  15.7 vs. 87.9 
17.7 points (P  0.001), respectively. The total GSC and
GWB indexes were significantly (P  0.05) worse in the
EH treated on regular basis (14.5% of males and 38.5%
of females) compared with EH who did not treat their
known hypertension. QL scores did not correlate (Spear-
man) with age, body mass index, office blood pressure,
and duration of hypertension. In males, but not in fe-
males there was an association (ANOVA) of the total
GSC index with alcohol and coffee consumption (stan-
dardized interview), while abstinents had the lowest
scores (P  0.05). The high QL score, smoking, drinking
and male gender were revealed as factors of poor C.
CONCLUSIONS: Gender influences on the QL profile in
EH living in Belarus, and relates to their C, possibly via
certain life-style factors, this requiring gender-based deci-
sion-making for hypertension management improvement.
PCV7
INCREMENTAL COST-EFFECTIVENESS RATIO 
IN ESTIMATION SOME HYPOTENSIVE DRUGS
Frisman M, Geltzer B
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OBJECTIVES: To investigate incremental cost-effective-
ness ratio (ICER) of some hypotensive drugs in elderly
patients with mild and moderate arterial hypertension.
METHODS: Analyses were based on patient data gath-
ered between January 1997 and August 1999 (n  210;
middle age 66,8  0,63). All these patients were divided
into seven groups. Six groups were treated monotherapy
by the following drugs: carvedilol, doxazosin, nifedipine-
GITS, enalapril maleat, indapamid, diltiazem. But the pa-
tients of the 7th group were not treated systematically by
various reasons. The received results were compared with
7th group. Supplementary effectiveness consisted of days
of successful treatment (DST). DST were included the
days where patient did not apply to in-patient, out-patient
and emergency care and also was not on dynamic obser-
vation and house hospital. RESULTS: ICER for patient
treated by nifedipine-GITS was $2,76 (95%; CI 0,7–
4,82). The number of DST was 78,27 (95%; CI 69,71–
86,83) per year. The indapamid group ($0,54) (95%;
CI (0,15)(0,93)) and 55,35 DST (95%; CI 51,07–
59,63). In enalapril group ($0,79) (95%; CI
(0,22)(1,36)) and 58,38 DST (95%; CI 48,93–67,83).
In diltiazem group ($1,6) (95%; CI (0,76)(2,44))
and 49,43 DST (95%; CI 43,25–55,61). In doxazosin
group $23,6 (95%; CI 11,52–35,68) and 37,62 DST
(95%; CI 31,5–43,74). In carvedilol group $3,0 (95%;
CI 1,74–4,26) and 71,42 DST (95%; CI 60,4–82,44).
CONCLUSION: ICER was compared expenditures and
effectiveness. It was revealed that using carvedilol and
nifedipine-GITS the patients had maximum of supple-
mentary successful days but it was required supplemen-
tary expenditures. Using indapamid, enalapril and dilt-
iazem the patients had less successful days but it was
economy, the expenditures were reduced. Using dox-
azosin the patients had few successful days and it was re-
quired considerable expenditures.
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OBJECTIVE: To model and predict hospitalization costs
after first acute coronary syndrome (ACS) based on age,
sex, social class, previous hospitalization for diabetes,
COAD and renal diseases. METHODS: The Cramer-
Lundberg insurance model was adapted to predict the
hospitalization costs within a given period. Three impor-
tant factors, costs per hospitalization, time to next hospi-
talization and time to death were modeled. The costs
were modeled by a gamma regression model using the
GEE approach to accommodate intra-patient correlation.
Parametric survival models were used for easy prediction.
Weibull regression was used for the recurrence of hospi-
talizations. Future costs can be predicted by combining
the models and using simulation. RESULTS: Average
costs increase with patient’s age. Compared with patients
over 80, the costs per hospital admission of those under
40 was only 44%. Previous hospitalization for diabetes,
COAD and renal diseases increases the costs by 25%,
12% and 12% respectively. Younger patients were more
likely to have a further hospitalization. The log-RR for
those under 40 is 0.36 (95% CI  0.24, 0.48) compared
with those over 80. On average, each previous ACS in-
creases the log-risk by 0.27 (95% CI  0.23, 0.31). Pre-
vious hospital admission for diabetes and renal diseases
also indicated higher risk with log-risk 0.34 (95% CI 
0.21, 0.47) and 0.53 (95%CI  0.28, 0.77) respectively.
Younger patients had lower mortality with log-RR for
those under 40 is 2.78 (95%CI  3.05, 2.50), com-
pared with those aged over 80. Previous hospital admis-
sions for diabetes, COAD and renal disease also indi-
cated higher mortality with log-RR 0.22 (95%CI  0.08,
0.36), 0.38 (95%CI  0.27, 0.49) and 0.86 (95%CI 
0.68, 1.03) respectively. CONCLUSION: The combined
model procedure provided a flexible approach to analyze
and predict hospitalization costs. Some factors may affect
the costs in several ways. This approach explored the role
of the factors in predicting individual costs.
